{"entity":{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","aka":[],"tldr":"Cell-free protein synthesis ADC company that refocused on exatecan and dual-payload ADCs, deprioritising its folate-receptor ADC luveltamab.","summary":"STRO-004 (tissue factor, DAR8 TOP1 payload) is the lead, with first clinical data expected mid-2026; STRO-227 is a DAR10 dual-payload PTK7 ADC (MMAE DAR2 + TOP1 DAR8) with IND planned 2026. Luveltamab tazevibulin (FRα) development stopped pending a partner. Site-specific conjugation via non-natural amino acids (XpressCF).","asOf":"2026-09-04","links":[{"label":"AACR 2026 pipeline data","url":"https://www.biospace.com/press-releases/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["adcs"],"technologies":["adc","dual-payload-adc","site-specific-conjugation"],"targets":["tissue-factor","folr1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.sutrobio.com","ticker":"STRO","investors":[],"funding":[]},"route":"/companies/sutro-biopharma/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"target":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/"},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/"}],"drug":[{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"}],"idea":[{"id":"idea-bio1-antibody-degrader-conjugates","kind":"idea","name":"Use antibodies to deliver protein-destroying drugs into the right cells","route":"/ideas/idea-bio1-antibody-degrader-conjugates/"}],"trial":[{"id":"nct05870748","kind":"trial","name":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","route":"/trials/nct05870748/"}]}}